Contact

Caixa Capital Risk invests in Inbiomotion


,
Integral service around a transaction
BY : Diego GutiérrezMarch Thu, 2016
It seems that biotechnology is finding investors in our country. A few weeks ago we told you that Inveready had invested in Cuantum and Ab-biotics, this week we learned that Oncostellae, which received a €1M round is looking for funding, and Caixa Capital Risk has led a €2.2M round in Inbiomotion.

la Caixa's investment in Inbiomotion

caixa

La Caixa through Caixa Innvierte BioMed IIhas led a €2.2M round in Inbiomotion, a spin-off of the Barcelona Biomedical Research Institute that develops diagnostic tests to predict the risk of cancer patients suffering from bone metastasis.

Also participating in the round were Ysios Capitalthe leading Spanish investment manager in the biotechnology sector, through its Ysios BioFund I, and the Vila Casas Foundation, which were already shareholders of the company.

This round will complete the clinical validation and make Inbiomotion's first product available to patients.

Inbiomotion's product, Osteomet, has already been validated in more than 1,300 patient samples from independent, multi-country cohorts and the company's primary goal is to complete its clinical and regulatory development within the next 2 years.

La Caixa is committed to biotechnology and creates Caixa Innvierte Start.

It is also in the news that last December the Caixa registered a new fund for technology SMEs with the CNMV, mainly for companies in the health and biotechnology sectors, although other sectors are not ruled out.

 La Caixa will focus on Spanish start-ups (although it does not rule out the "exceptional" possibility of making purchases in other geographies as long as they do not consume 20% of the total resources raised by the fund) and with an outstanding potential for innovation and growth.

These general guidelines are quite favourable for the new fund to receive the injection of the government's fund of funds articulated through the ICO, Fond-ICO Global -whose sixth call remains open until 29 March. In fact, in the management regulations that Caixa Innvierte Start has submitted to the CNMV, there is a specific article (article 17) that regulates the intervention of public participants.

If you are looking for financing, please contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.

Other posts that may interest you

Inveready bets on biotechnology, invests in Cuantum and AB-Biotics in less than a month

Investors lose their fear of investing in biotechnology

Biotech operations: Minoryx, Suanfarma, Ability Pharma and Oryzon Genomics

The M&A Professionals

Meet our services

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
closearrow-circle-o-downchevron-downcrossmenu